Why the study?
Does ramipril reduce atherosclerosis in apolipoprotein E-deficient mice independently of its antihypertensive effect and bradykinin potentiation?
Population
Apolipoprotein (apo) E-deficient mice
Comparison
Ramipril supplemented in drinking water, with or… vs Placebo
Design
Preclinical
Follow-up
10 weeks
Authors
Loading...
Hypothesis-generating for angiotensin II inhibition in atherosclerosis beyond BP or bradykinin effects; does not inform clinical practice.
Does ramipril reduce atherosclerosis in apolipoprotein E-deficient mice independently of its antihypertensive effect and bradykinin potentiation?
Ramipril attenuates atherosclerosis in apo E-deficient mice independently of blood pressure reduction and bradykinin potentiation, suggesting the effect is mediated through inhibition of angiotensin II production.
Keidar et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: